We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
935-P: Favorable Shift in CGM Glucose in Youth with T1D during COVID-19 Pandemic.
- Authors
KAUSHAL, TARA; TINSLEY, LIANE J.; VOLKENING, LISA K.; AMBLER-OSBORN, LOUISE; LAFFEL, LORI M.
- Abstract
Aim: COVID-19 caused disruption with potential for changes in lifestyle and T1D care behaviors, especially for youth. We compared CGM-derived glucometrics during the COVID-19 pandemic with the previous year in a clinic-based pediatric sample with T1D using CGM. Method: We used EHR-extracted data to compare CGM metrics during the pandemic (3/16/20 -10/29/20) with the same calendar months in 2019. The sample comprised youth using CGM, aged 1-18 years, with T1D duration ≥6 months (age <6 years) or ≥1 year (age ≥6 years). Results: The pre-pandemic sample comprised 578 youth (53% female, age 12.4±3.5, T1D 6.2±3.5 years). The pandemic sample comprised 605 youth (54% female, age 13.4±3.6, T1D 6.8±3.8 years). Over 80% of youth were common to both samples. Mean CGM glucose was 7 mg/dL lower during the pandemic (186±35) vs. pre-pandemic (193±33) (p<.001). The proportion of youth with mean glucose <145 and 145-154 mg/dL increased 80-100% during the pandemic (5 to 9% and 5 to 10%, respectively), while the proportion with mean glucose ≥210 mg/dL decreased by 29% (31 to 22%). The % of youth with glucose management indicator (GMI) <7% increased by >110% (Figure). The 7-12y age group showed the largest shift in GMI: 8.0 pre- vs. 7.7% during pandemic (p=.003). Conclusion: There was a beneficial shift in glucose levels from pre to during the pandemic. Future studies are needed to assess how changes in healthcare during the pandemic may have improved glycemic outcomes. Disclosure: T. Kaushal: None. L. J. Tinsley: None. L. K. Volkening: None. L. Ambler-osborn: None. L. M. Laffel: Consultant; Self; AstraZeneca, Boehringer Ingelheim International GmbH, Dexcom, Inc., Dompe, Insulogic LLC, Janssen Pharmaceuticals, Inc., Laxmi Therapeutic Devices, LifeScan, Lilly Diabetes, Medtronic, Provention Bio, Inc. Funding: National Institutes of Health (K12DK094721, P30DK036836)
- Publication
Diabetes, 2021, Vol 70, pN.PAG
- ISSN
0012-1797
- Publication type
Article
- DOI
10.2337/db21-935-P